Select Publications
Other
2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, , http://dx.doi.org/10.1158/1078-0432.c.6762576
,2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, , http://dx.doi.org/10.1158/1078-0432.c.6762576.v2
,2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, , http://dx.doi.org/10.1158/1078-0432.24071513
,2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, , http://dx.doi.org/10.1158/1078-0432.24071513.v1
,2023, Data from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, , http://dx.doi.org/10.1158/1078-0432.c.6762576.v1
,2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, , http://dx.doi.org/10.1158/1078-0432.23791947
,2023, Supplementary Data 1 from A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer, , http://dx.doi.org/10.1158/1078-0432.23791947.v1
,